Please login to the form below

Not currently logged in
Email:
Password:

Merck acquires US life sciences company

Merck has announced the completion of its acquisition of US life sciences company, Millipore, for $7bn

Germany-based pharmaceutical company, Merck, has announced the completion of its acquisition of US life sciences company, Millipore for a purchase price, including debt and cash, of around $7bn. The companies had agreed the deal in February 2010.

The acquisition's closure follows approval from Millipore's shareholders for the deal which will see the launch of a new division of Merck Chemicals to be called Merck Millipore. Head of Merck Chemicals, Dr Bernd Reckmann, will also assume leadership of Merck Millipore while remaining in his present role.

"The increased breadth of the Merck Millipore product portfolio, together with the expertise of our talented people, will allow us to deepen our customer relationships and gain the new insights we need to further drive innovation," said Dr Reckmann.

"We will also bring together our research and development capabilities, which will make Merck Millipore one of the top three investors in R&D in the Life Science Tools industry. This, in turn, will enable us to create greater value for our customers."

Merck Millipore will be based in Massachusetts, US, with supporting locations throughout the Americas, Europe and Asia-Pacific.

The new division will consist of 10,000 employees in 64 countries, with three business units focusing on bioscience, lab solutions and process solutions.

A range of products, technologies and services for pharma and biotechnology companies to improve productivity in both R&D and manufacturing will be provided by Merck Millipore.

Millipore CEO, Martin Madaus, will not join Merck Millipore but will act as an advisor during the integration process. The majority of this process is expected to be completed by the end of 2010, according to Merck.

15th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...